|
WHO Updates on Nitrosamine Impurities
|
|
0
|
289
|
October 30, 2025
|
|
N-Nitroso Sertraline
|
|
9
|
780
|
October 23, 2025
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
10
|
626
|
September 22, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
18
|
4879
|
September 20, 2025
|
|
Nitrosamines risk in cleaning validation approach
|
|
11
|
317
|
September 4, 2025
|
|
Ask for help with limit for Nitroso-olaparib
|
|
2
|
161
|
September 4, 2025
|
|
👨💻 Quantitative Analysis of NDMA, N-Nitroso-l-ephedrine and N-Nitroso-pseudoephedrine in Pseudoephedrine Hydrochloride by HPLC-Tandem MS
|
|
2
|
400
|
August 28, 2025
|
|
Three-Pronged Approach (Active Pharmaceutical Ingredients, Excipients, and NOx-Free Air) Successfully Suppressed the Formation of Nitroso-atomoxetine to 0.097 ppm
|
|
0
|
413
|
August 24, 2025
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
4161
|
August 18, 2025
|
|
Testing of N-nitroso-cinacalcet
|
|
6
|
799
|
May 25, 2025
|
|
Primary amines in formation of nitrosamine
|
|
6
|
742
|
August 13, 2025
|
|
Nitrosamine Risk Mitigation Calculator (by DFE Pharma)
|
|
1
|
880
|
August 11, 2025
|
|
🇺🇸 FDA - Fiscal Year 2024 Generic Drug Science and Research Initatives Public Workshop
|
|
21
|
2084
|
August 7, 2025
|
|
Highlights from the 13th meeting of the Nitrosamine Implementation Oversight Group (NIOG)
|
|
7
|
484
|
July 22, 2025
|
|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
252
|
July 12, 2025
|
|
CMO Nitrosamine Risk Assessment
|
|
7
|
422
|
June 27, 2025
|
|
Analytical Method Development Strategy for Controlling Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for Treatment of a Rare Disease -Pub
|
|
0
|
91
|
June 25, 2025
|
|
Optimizing Pharmaceutical Formulations: Strategies for Improving Stability and Minimizing Nitrosamine Impurities-Webinar
|
|
1
|
303
|
June 20, 2025
|
|
Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity Data-Pub
|
|
0
|
208
|
June 6, 2025
|
|
N-Nitroso Abemaciclib
|
|
8
|
332
|
June 4, 2025
|
|
¹⁵N-Enriched NAP Test
|
|
0
|
213
|
May 31, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
33
|
2385
|
May 27, 2025
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
17
|
730
|
May 23, 2025
|
|
N-Nitroso Spinosad Impurity-A and Impurity-D
|
|
2
|
206
|
May 21, 2025
|
|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
118
|
May 13, 2025
|
|
Understanding Aqueous Nitrosation Kinetics of 4-Substituted Piperidines To Risk Assess Pharmaceutical Processes and Products-Pub
|
|
1
|
196
|
May 6, 2025
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3422
|
May 2, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
6427
|
April 30, 2025
|
|
N-nitroso-deucravacitinib
|
|
9
|
400
|
April 29, 2025
|
|
🕵🏻 OTC Market Withdrawal of Diphenhydramine
|
|
0
|
533
|
April 24, 2025
|